Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.10
-0.12 (-0.79%)
At close: Mar 6, 2026, 4:00 PM EST
15.06
-0.04 (-0.26%)
After-hours: Mar 6, 2026, 5:51 PM EST
Nurix Therapeutics Employees
Nurix Therapeutics had 317 employees as of November 30, 2025. The number of employees increased by 31 or 10.84% compared to the previous year.
Employees
317
Change (1Y)
31
Growth (1Y)
10.84%
Revenue / Employee
$264,921
Profits / Employee
-$834,249
Market Cap
1.55B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Intellia Therapeutics | 377 |
| Harmony Biosciences Holdings | 293 |
| Innoviva | 159 |
| Tango Therapeutics | 155 |
NRIX News
- 5 weeks ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics: Why This Company Could Double In Value? - Seeking Alpha
- 7 weeks ago - Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside - Seeking Alpha
- 7 weeks ago - Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript - Seeking Alpha
- 3 months ago - Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire